AstraZeneca today announced a $3.5 billion investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion in new investments creating more than 1,000 new high-skilled jobs that will help grow the U.S. economy.
AstraZeneca’s expanded presence in the United States includes, among other things:
- A state-of-the-art R&D center in the Kendall Square neighborhood of Cambridge, Massachusetts
- Next-Generation Biologics Manufacturing Plant in Maryland
- Cell therapy production capacity on the West and East coasts
- Specialty Manufacturing in Texas
Pascal Soriot, AstraZeneca’s Chief Executive Officer, said: ” Our multi-billion dollar investment reflects the attractiveness of the business environment and the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support America’s leadership in healthcare innovation.”
Ensuring growth: Ambition 2030
These US investments are the first in a series of important steps to help AstraZeneca achieve its ambition of reaching $80 billion in total sales by 2030, as outlined in May this year . A key part of our strategy is to accelerate the business’s development in the US. The US is AstraZeneca’s largest market, generating 44% of its total sales. 1
AstraZeneca in the United States
AstraZeneca has approximately 17,800 employees across 17 R&D, manufacturing and marketing sites in 12 states.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-driven biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines in the areas of oncology, rare diseases and biopharmaceuticals, including Cardiovascular, Renal and Metabolism, and Respiratory and Immunology. Headquartered in Cambridge, UK, AstraZeneca sells its innovative medicines in more than 125 countries and administers them to millions of patients worldwide. Visit astrazeneca.com and follow the company on social media @AstraZeneca.
